TMCnet News
Downtrend Call Working As Spectrum Pharmaceuticals Stock Falls 37.1% (SPPI)Apr 04, 2013 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified a Downtrend for Spectrum Pharmaceuticals (NASDAQ:SPPI) on February 26th, 2013 at $11.22. In approximately 1 month, Spectrum Pharmaceuticals has returned 37.08% as of today's recent price of $7.06. Spectrum Pharmaceuticals share prices have moved between a 52-week high of $17.48 and a 52-week low of $6.92 and are now trading 2% above that low price at $7.06 per share. The 200-day and 50-day moving averages have moved 0.54% lower and 2.7% lower over the past week, respectively. Spectrum Pharmaceuticals Inc. develops in-licensed drugs for the treatment and supportive care of cancer patients. The Company's satraplatin is an oral, anti-cancer drug. Spectrum's Elsamitrucin targets non-Hodgkin's lymphoma, and Neoquin is being studied in the treatment of superficial bladder cancer. Spectrum also has a pipeline of pre-clinical neurological drug candidates. SmarTrend will continue to scan these moving averages and a number of other proprietary indicators for any changes in momentum for shares of Spectrum Pharmaceuticals. Log in and add Spectrum Pharmaceuticals (SPPI) to your watchlist today so you can receive a real-time alert when the shares are about to change trend. Write to Chip Brian at [email protected] --------------------------------------------------------------------------------------------- SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.MySmarTrend.com Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.MySmarTrend.com/signup |